Cel Sci (CVM) Total Non-Current Liabilities (2010 - 2026)
Cel Sci (CVM) posted Total Non-Current Liabilities of $10.7 million for Q1 2026, down 7.94% sequentially from $11.6 million in Q4 2025, and down 21.75% YoY from $13.7 million in Q1 2025.
Cel Sci (CVM) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Cel Sci has reported Total Non-Current Liabilities for 16 years, with the latest figure at $10.7 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 21.75% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (down 21.75% YoY) and the FY2025 annual result came in at $12.1 million, down 13.76% from the prior year.
- Total Non-Current Liabilities slipped to $10.7 million in Q1 2026 per CVM's latest filing, from $11.6 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $18.9 million in Q1 2022 and troughed at $10.7 million in Q1 2026.
- A 5-year average of $15.4 million and a median of $15.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities climbed 12.88% in 2022, then slipped 21.75% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $17.8 million in 2022, then dropped by 10.68% to $15.9 million in 2023, then fell by 10.48% to $14.3 million in 2024, then dropped by 18.47% to $11.6 million in 2025, then slipped by 7.94% to $10.7 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $10.7 million, $11.6 million, and $12.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 10.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.71 Mn |
| Dec 31, 2025 | 11.63 Mn |
| Sep 30, 2025 | 12.07 Mn |
| Jun 30, 2025 | 13.19 Mn |
| Mar 31, 2025 | 13.68 Mn |
| Dec 31, 2024 | 14.27 Mn |
| Sep 30, 2024 | 14.00 Mn |
| Jun 30, 2024 | 15.47 Mn |
| Mar 31, 2024 | 15.62 Mn |
| Dec 31, 2023 | 15.93 Mn |
| Sep 30, 2023 | 17.19 Mn |
| Jun 30, 2023 | 17.40 Mn |
| Mar 31, 2023 | 17.92 Mn |
| Dec 31, 2022 | 17.84 Mn |
| Sep 30, 2022 | 18.24 Mn |
| Jun 30, 2022 | 18.04 Mn |
| Mar 31, 2022 | 18.91 Mn |
| Dec 31, 2021 | 18.20 Mn |
| Sep 30, 2021 | 19.21 Mn |
| Jun 30, 2021 | 19.72 Mn |